NASDAQ$ENGN
enGene Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Announced second quarter 2024 financial results and provided a business update, including plans for initial indication expansion for EG-70 into high-risk papillary only NMIBC.
enGene reported its second quarter 2024 financial results, highlighting a net loss of $15.0 million, or $0.38 per share, and cash and cash equivalents of $264.8 million. The company is expanding the LEGEND study to include a cohort focused on enrollment of patients with high-risk, BCG-unresponsive papillary-only NMIBC.
- Plans to expand LEGEND study to include a cohort focused on patients with high-risk, BCG-unresponsive papillary-only NMIBC.
- Expects to release interim data from the LEGEND study’s BCG-unresponsive cohort by the end of September 2024.
- Enrollment in the second cohort of LEGEND study has been temporarily paused, with enrollment in both groups expected to resume in the fourth quarter of 2024.
- Cash and cash equivalents were $264.8 million as of April 30, 2024, expected to fund operations into 2027.
Headline financials
Revenue & EPS history
Engene · Revenue · Quarterly
$0
Forward guidance
enGene anticipates releasing interim data from LEGEND Cohort 1 by the end of September and expects to file a BLA for EG-70 in mid-2026. The company plans to expand the LEGEND study to include a third cohort targeting high-risk BCG-unresponsive papillary-only NMIBC patients and modifying the second cohort to include BCG-exposed patients.
Tailwinds
- Release of interim data from LEGEND Cohort 1 by the end of September.
- Expansion of LEGEND study to include a third cohort targeting high-risk BCG-unresponsive papillary-only NMIBC patients.
- Modification of the second cohort of LEGEND study to include BCG-exposed patients.
- Existing cash and cash equivalents will fund operating expenses, debt obligations and capital expenditures into 2027.
- Planned initial expansion of the LEGEND study will include a cohort focused on enrollment of patients with high-risk, BCG-unresponsive papillary-only NMIBC.
Headwinds
- Temporary pause in enrollment in the second cohort of LEGEND study.
- Deprioritization of pre-clinical development of EG-i08 for cystic fibrosis.
- Increase in operating expenses due to increasing manufacturing and clinical costs related to the EG-70 study.
- Increase in general and administrative expenses due to headcount costs and professional fees.
- Net loss attributable to common shareholders was approximately $15.0 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q2 2024
-2.6%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+17.4%
Avg return
30 days after
43%
6 / 14 earnings
Positive
+5.3%
Q4 2025
Best reaction
-18.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -18.9% | -17.5% | -15.8% | |
| Q4 2025 | +5.3% | +8.3% | +21.3% | |
| Q3 2025 | -6.3% | +7.6% | +38.4% | |
| Q2 2025 | -0.9% | +0.9% | +2.8% | |
| Q1 2025 | +4.9% | -10.1% | -22.3% | |
| Q4 2024 | -1.7% | +6.6% | +20.4% | |
| Q3 2023 | +1.8% | +1.7% | +4.3% | |
| Q3 2024 | +1.8% | +1.7% | +4.3% | |
| Q2 2024 | -13.5% | -16.4% | -9.3% | |
| Q2 2023 | -13.5% | -16.4% | -9.3% | |
| Q1 2024 | +4.9% | +5.2% | -1.6% | |
| Q1 2023 | +4.9% | +5.2% | -1.6% | |
| Q4 2023 | -2.7% | +0.5% | +106.1% | |
| Q4 2022 | -2.7% | +0.5% | +106.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro